IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Investors, media and stakeholders are invited to join in person in
To register to attend the event in person or virtually, please RSVP by clicking here.
"We look forward to gathering with investors and scientific leaders to showcase key progress across our IMNN-001 clinical program," said
The event will feature a conversation with an OVATION 1 clinical trial participant offering a firsthand perspective on her experience in the study and in the years following the trial. Presentations will include leading experts in ovarian cancer and principal investigators involved in the Company's Phase 3 OVATION 3 clinical trial and the Phase 2 minimal residual disease (MRD) clinical trial, conducted in partnership with the Break Through
Members of
Featured Presentations and Speakers:
- Redefining Frontline Care — Unlocking the Potential of a First-in-Class IL-12 Immunotherapy in Ovarian Cancer
Presenter:Stacy R. Lindborg , Ph.D., President and Chief Executive Officer,IMUNON, Inc. - Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas™ Delivery of IMNN-001
Presenter:Douglas V. Faller , M.D., Ph.D., Chief Medical Officer,IMUNON, Inc. - Unveiling Translational Insights — MRD Clearance, Microenvironment Remodeling, and Combination Strategies
Presenter:Amir Jazaeri , M.D., Vice Chair for Clinical Research, Director, Gynecologic Cancer Immunotherapy Program,Department of Gynecologic Oncology and Reproductive Medicine ,University of Texas MD Anderson Cancer Center - Advancing Frontline Efficacy — Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3
Presenter:Premal H. Thaker , M.D., David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Chief of Gynecologic Oncology, Director ofGynecologic Oncology Clinical Research , Professor in Gynecologic Oncology,Washington University School of Medicine - Beyond the Data: Clinical Experience with IMNN-001 — A Conversation with an OVATION 1 Study Participant
Presenter: OVATION 1 clinical trial participant, withWilliam Bradley , M.D., Professor and Vice Chair for Clinical Research,Division of Gynecologic Oncology ,Medical College of Wisconsin - Building the Future — Strategic Milestones, Catalysts, and the Investment Horizon
Presenter:Stacy R. Lindborg , Ph.D., President and Chief Executive Officer,IMUNON, Inc.
About IMNN-001 Immunotherapy
Designed using
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.
The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in the ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 is designed to instruct the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Investors Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com
